WASHINGTON--(BUSINESS WIRE)--Targanta Therapeutics Corporation (NASDAQ: TARG) today announced the presentation of studies detailing oritavancin’s superior in vitro potency at the combined annual meetings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA), taking place in Washington, DC. These presentations highlight oritavancin’s potent activity against a variety of gram-positive bacteria, including those strains either non-susceptible or resistant to currently available agents. The preclinical research underscores oritavancin’s potential to address the limitations of currently marketed therapies for serious gram-positive infections.
